ALK and non-small cell lung carcinoma: In the clinical setting, the RET patient benefit in terms of response (16% to 47%), and PFS (2 to 7 months), is clearly not comparable to that seen with other targeted agents in NSCLC patient bearing EGFR mutation (ORR: 56%–85%, median PFS: 9.2–13.7 months) [71], ALK (ORR: 60%–95%, median PFS: 8–11 months) [72] or ROS1 (ORR: 65%–85%, median PFS: 9.1–19.3 months) rearrangements [73].